Dateline City:
KENILWORTH, N.J.
Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its
investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have
100 percent efficacy in an analysis of interim data from a Phase 3 ring
vaccination trial in Guinea. Preliminary conclusions from this study,
which is continuing, were published on-line today in The Lancet.
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 267-305-3558orInvestor Contacts:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more